Results 121 to 130 of about 6,421 (186)

Molnupiravir in Combination With Nirmatrelvir/Ritonavir: No Cause for Alarm. [PDF]

J Infect Dis
Kuritzkes DR.
europepmc   +1 more source

Risk Factors for Seeking Medical Care Following Nirmatrelvir-Ritonavir (Paxlovid) Treatment for COVID-19: "Symptom Rebound". [PDF]

Viruses
Bhargava A, Szpunar S, Sharma M, Saravolatz L.   +3 more
europepmc   +1 more source

Cost-Effectiveness of Nirmatrelvir/Ritonavir in COVID-19 Patients at High-Risk for Progression in Spain. [PDF]

J Med Virol
Azanza JR, González Del Castillo JM, Ferrando R, Molero JM, Soriano A, Peral C, de Lossada A, Bellmunt A, Garí C, Mugwagwa T, López-Gómez V.   +10 more
europepmc   +1 more source

Risk of Post-COVID-19 Conditions Among Adolescents and Adults Who Received Nirmatrelvir-Ritonavir for Acute COVID-19: A Retrospective Cohort Study. [PDF]

Open Forum Infect Dis
Dalton AF, Baca S, Raykin J, Gregory CO, Boehmer T, Koumans EH, Patel PR, Patel P, Saydah S.   +8 more
europepmc   +1 more source

Nirmatrelvir/ritonavir in heart transplant recipients with COVID-19: A case report on pharmaceutical care and drug interaction management. [PDF]

Medicine (Baltimore)
Zhang J, Su J, Yu X, Yue W, Chen J, Xu L.   +5 more
europepmc   +1 more source

Symptom Alleviation/Resolution and Returns to Usual Health/Activities in Immunocompromised Adults with COVID-19 Treated with Nirmatrelvir-Ritonavir: Results from the EPIC-IC Trial. [PDF]

Infect Dis Ther
Mokgokong R, Cislo P, Tudone E, Weinstein E, Cappelleri JC.   +4 more
europepmc   +1 more source

Efficacy and safety of azvudine versus nirmatrelvir/ritonavir in cancer patients with COVID-19. [PDF]

Sci Rep
Jia B, Sun J, Zhu D, Wang L, Hu X, Wang H, Qian G, Zhang D, Li S, Luo H, Zhang S, Li G, Li G, Liang H, Yu Z, Ren Z.   +15 more
europepmc   +1 more source